InvestWiserDicot AB
DICOT · Nasdaq Stockholm · Healthcare
0.22SEK
−1.6%last day
Price as of 2 October 2026
Performance
1 month
−12.9%
1 year
−73.0%
3 years, per year
+14.4%
5 years, per year
−20.5%
Largest fall, 3 years
−93.3%
Below the peak now
−95.0%
Volatility, 1 year
109.1%
Return with dividends reinvested.
Key figures
P/E
negative earnings
P/B
2.9
Dividend yield
0.0%
Return on equity
−19.6%
Net margin
–
Market value
76 m USD
Quality, value and trend
Where Dicot stands against every Nordic stock today. 100 is best.
59
Profitability and a sound balance sheet over time. Better than 59% of Nordic stocks.
8
The price measured against earnings, assets and cash flow. Better than 8% of Nordic stocks.
25
The price development over the past year. Better than 25% of Nordic stocks.
14
Quality, value and trend together. Better than 14% of Nordic stocks.
About Dicot
Dicot AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 4 employees.
Dicot Pharma AB engages in the development of pharmaceutical products in Sweden. It develops LIB-01 that is in Phase 2a clinical trial for the treatment of erectile dysfunction and under medical discovery for treating premature ejaculation. The company was formerly known as Dicot AB (publ) and changed its name to Dicot Pharma AB in May 2024. Dicot Pharma AB was incorporated in 2015 and is based in Uppsala, Sweden.
See the full analysis in InvestWiser.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
See the full analysis